Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of TQ-B3234 in NF1 and MPNST
NCT05107037Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tunlametinib in neurofibromatosis type 1 (NF1) and malignant peripheral nerve sheath tumor (MPNST), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 48 weeks, Dose Limiting Toxicity at 4 weeks and 2 more. Status: unknown.
02
Drugs
tunlametinib
03
Conditions
neurofibromatosis type 1 (NF1)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT05107037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05107037.